Induction of humoral and cell-mediated immune responses by hepatitis B virus epitope displayed on the virus-like particles of prawn nodavirus

Applied and Environmental Microbiology

Volumn 81, Issue 3, 2015, Pages 882-889

  Yong, Chean Yeah ^a   Yeap, Swee Keong ^a   Goh, Zee Hong ^a   Ho, Kok Lian ^a   Omar, Abdul Rahman ^a   Tan, Wen Siang ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

AFFINITY CHROMATOGRAPHY; PURIFICATION; RECOMBINANT PROTEINS; SILVER COMPOUNDS; SUPPORT VECTOR MACHINES; TRANSMISSION ELECTRON MICROSCOPY; VACCINES; VIRUSES; YEAST;

CELL-MEDIATED IMMUNE; CHIMERIC PROTEINS; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; MACROBRACHIUM ROSENBERGII; PURIFIED PROTEIN; VIRUS-LIKE PARTICLES;

EPITOPES;

ANTIGEN; GERM CELL; HEPATITIS; IMMUNE RESPONSE; IMMUNIZATION; PROTEIN; SECRETION; VACCINE; VIRUS; YEAST;

HEPATITIS B VIRUS; MACROBRACHIUM ROSENBERGII NODAVIRUS; MIRIDAE; MUS; NODAVIRIDAE; SACCHAROMYCES CEREVISIAE;

DRUG CARRIER; EPITOPE; GAMMA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT VACCINE; VIRUS LIKE PARTICLE VACCINE;

ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL SURFACE DISPLAY; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; NATURAL KILLER CELL; NODAVIRIDAE; SECRETION (PROCESS); T LYMPHOCYTE; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; CELL SURFACE DISPLAY TECHNIQUES; DRUG CARRIERS; EPITOPES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NODAVIRIDAE; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84921415245     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.03695-14     Document Type: Article

References (56)

1. Lavanchy D. 2005. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34:S1-S3. http://dx.doi.org/10.1016/S1386-6532(05)00384-7.
2. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. 2006. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28:112-125. http://dx.doi.org/10.1093/epirev/mxj009.
3. Bruss V, Ganem D. 1991. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci U S A 88:1059-1063. http://dx.doi.org/10.1073/pnas.88.3.1059.
4. Dane DS, Cameron CH, Briggs M. 1970. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet i:695-698.
5. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. 1984. Human hepatitis B vaccine from recombinant yeast. Nature 307:178-180. http://dx.doi.org/10.1038/307178a0.
6. Murray K, Bruce SA, Wingfield P, van Eerd P, De Reus A, Schellekens H. 1984. Hepatitis B virus antigen made in microbial cells immunise against viral infection. EMBO J 3:645-650.
7. Howard CR, Allison LM. 1995. Hepatitis B surface antigen variation and protective immunity. Intervirology 38:35-40.
8. Tan GH, Yusoff K, Seow HF, Tan WS. 2005. Antigenicity and immunogenicity of the immunodominant region of hepatitis B surface antigen displayed on bacteriophage T7. J Med Virol 77:475-480. http://dx.doi.org/10.1002/jmv.20479.
9. Ottone S, Nguyen X, Bazin J, Berard C, Jimenez S, Letourneur O. 2007. Expression of hepatitis B surface antigen major subtypes in Pichia pastoris and purification for in vitro diagnosis. Protein Expr Purif 56:177-188. http://dx.doi.org/10.1016/j.pep.2007.07.008.
10. Coleman PF. 2006. Detecting hepatitis B surface antigen mutants. Emerg Infect Dis 12:198-203. http://dx.doi.org/10.3201/eid1203.050038.
11. Pawlotsky JM. 2005. The concept of hepatitis B virus mutant escape. J Clin Virol 34:S125-S129. http://dx.doi.org/10.1016/S1386-6532(05)80021-6.
12. Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, Thomas H, Zuckerman AJ. 1988. Hepatitis B variant in Europe. Lancet ii:1132-1133.
13. Zuckerman JN, Zuckerman AJ. 2003. Mutations of the surface protein of hepatitis B virus. Antiviral Res 60:75-78. http://dx.doi.org/10.1016/j.antiviral.2003.08.013.
14. Lapiń ski TW, Pogorzelska J, Flisiak R. 2012. HBV mutations and their clinical significance. Adv Med Sci 57:18-22. http://dx.doi.org/10.2478/v10039-012-0006-x.
15. Tan WS, Ho KL. 2014. Phage display creates innovative applications to combat hepatitis B virus. World J Gastroenterol 20:11650-11670. http://dx.doi.org/10.3748/wjg.v20.i33.11650.
16. Arcier JM, Herman F, Lightner DV, Redman RM, Mari J, Bonami JR. 1999. A viral disease associated with mortalities in hatchery-reared postlarvae of the giant freshwater prawn Macrobrachium rosenbergii. Dis Aquat Organ 38:177-181. http://dx.doi.org/10.3354/dao038177.
17. Saedi TA, Moeini H, Tan WS, Yusoff K, Daud HM, Chu KB, Tan SG, Bhassu S. 2012. Detection and phylogenetic profiling of nodavirus associated with white tail disease in Malaysian Macrobrachium rosenbergii de Man. Mol Biol Rep 39:5785-5790. http://dx.doi.org/10.1007/s11033-011-1389-7.
18. Goh ZH, Tan SG, Bhassu S, Tan WS. 2011. Virus-like particles of Macrobrachium rosenbergii nodavirus produced in bacteria. J Virol Methods 175:74-79. http://dx.doi.org/10.1016/j.jviromet.2011.04.021.
19. Goh ZH, Mohd NA, Tan SG, Bhassu S, Tan WS. 2014. RNA-binding region of Macrobrachium rosenbergii nodavirus capsid protein. J Gen Virol 95:1919-1928. http://dx.doi.org/10.1099/vir.0.064014-0.
20. Lee KW, Tey BT, Ho KL, Tan WS. 2012. Delivery of chimeric hepatitis B core particles into liver cells. J Appl Microbiol 112:119-131. http://dx.doi.org/10.1111/j.1365-2672.2011.05176.x.
21. Lee KW, Tey BT, Ho KL, Tejo BA, Tan WS. 2012. Nanoglue: an alternative way to display cell-internalizing peptide at the spikes of hepatitis B virus core nanoparticles for cell-targeting delivery. Mol Pharm 9:2415-2423. http://dx.doi.org/10.1021/mp200389t.
22. Petry H, Goldmann C, Ast O, Luke W. 2003. The use of virus-like particles for gene transfer. Curr Opin Mol Ther 5:524-528.
23. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89:12180-12184. http://dx.doi.org/10.1073/pnas.89.24.12180.
24. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. 2003. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitisCvirus-vaccinia infection. Proc Natl Acad SciUSA 100:6753-6758. http://dx.doi.org/10.1073/pnas.1131929100.
25. Murray K, Shiau AL. 1999. The core antigen of hepatitis B virus as a carrier for immunogenic peptides. Biol Chem 380:277-283.
26. Quan FS, Compans RW, Nguyen HH, Kang SM. 2008. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 82:1350-1359. http://dx.doi.org/10.1128/JVI.01615-07.
27. Yap WB, Tey BT, Alitheen NB, Tan WS. 2012. Display of the antigenic region of Nipah virus nucleocapsid protein on hepatitis B virus capsid. J Biosci Bioeng 113:26-29. http://dx.doi.org/10.1016/j.jbiosc.2011.09.007.
28. Chackerian B, Caldeira JDC, Peabody J, Peabody DS. 2011. Peptide epitope identification by affinity selection on bacteriophage MS2 viruslike particles. J Mol Biol 409:225-237. http://dx.doi.org/10.1016/j.jmb.2011.03.072.
29. Tan WS, Dyson MR, Murray K. 1999. Two distinct segments of the hepatitis B virus surface antigen contribute synergistically to its association with the viral core particles. J Mol Biol 286:797-808. http://dx.doi.org/10.1006/jmbi.1998.2525.
30. Birnboim HC, Doly J. 1979. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res 7:1513-1523. http://dx.doi.org/10.1093/nar/7.6.1513.
31. Ho CW, Chew TK, Ling TC, Kamaruddin S, Tan WS, Tey BT. 2006. Efficient mechanical cell disruption of Escherichia coli by an ultrasonicator and recovery of intracellular hepatitis B core antigen. Process Biochem 41:1829-1834. http://dx.doi.org/10.1016/j.procbio.2006.03.043.
32. Ibanez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, Pollard C, Schepens B, Grooten J, Fiers W, Saelens X. 2013. M2edisplaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PLoS One 8:e59081. http://dx.doi.org/10.1371/journal.pone.0059081.
33. Matic S, Rinaldi R, Masenga V, Noris E. 2011. Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol 11:106. http://dx.doi.org/10.1186/1472-6750-11-106.
34. Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, Mokhtari-Azad T. 2012. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS One 7:e45765. http://dx.doi.org/10.1371/journal.pone.0045765.
35. Sominskaya I, Skrastina D, Dislers A, Vasiljev D, Mihailova M, Ose V, Dreilina D, Pumpens P. 2010. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin Vaccine Immunol 17:1027-1033. http://dx.doi.org/10.1128/CVI.00468-09.
36. Vietheer PT, Boo I, Drummer HE, Netter HJ. 2007. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir Ther 12:477-487.
37. Wang YS, Ouyang W, Liu XJ, He KW, Yu SQ, Zhang HB, Fan HJ, Lu CP. 2012. Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV. Vaccine 30:2125-2130. http://dx.doi.org/10.1016/j.vaccine.2012.01.040.
38. Jackwood DJ. 2013. Multivalent virus-like-particle vaccine protects against classic and variant infectious bursal disease viruses. Avian Dis 57:41-50. http://dx.doi.org/10.1637/10312-080212-Reg.1.
39. Kanai Y, Athmaram TN, Stewart M, Roy P. 2013. Multiple large foreign protein expression by a single recombinant baculovirus: a system for production of multivalent vaccines. Protein Expr Purif 91:77-84. http://dx.doi.org/10.1016/j.pep.2013.07.005.
40. Pride MW, Shi H, Anchin JM, Linthicum DS, LoVerde PT, Thakur A, Thanavala Y. 1992. Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide. Proc Natl Acad Sci U S A 89:11900-11904. http://dx.doi.org/10.1073/pnas.89.24.11900.
41. Ryu CJ, Gripon P, Park HR, Park SS, Kim YK, Guguen-Guillouzo C, Yoo OJ, Hong HJ. 1997. In vitro neutralization of hepatitis B virus by monoclonal antibodies against the viral surface antigen. J Med Virol 52: 226-233. http://dx.doi.org/10.1002/(SICI)1096-9071(199706)52:2(226 ::AID-JMV18)3.0.CO;2-I.
42. Arase H, Arase N, Saito T. 1996. Interferon gamma production by natural killer (NK) cells and NK1.1+T cells upon NKR-P1 cross-linking. J Exp Med 183:2391-2396. http://dx.doi.org/10.1084/jem.183.5.2391.
43. Wang R, Jaw JJ, Stutzman NC, Zou Z, Sun PD. 2012. Natural killer cell-produced IFN-γ and TNF-γ induce target cell cytolysis through upregulation of ICAM-1. J Leukoc Biol 91:299-309. http://dx.doi.org/10.1189/jlb.0611308.
44. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. 2000. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192:921-930. http://dx.doi.org/10.1084/jem.192.7.921.
45. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. 2003. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77:68-76. http://dx.doi.org/10.1128/JVI.77.1.68-76.2003.
46. Bertoletti A, Maini M, Williams R. 2003. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res 60:61-66. http://dx.doi.org/10.1016/j.antiviral.2003.08.012.
47. Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. 2010. CD8+ T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 184:287-295. http://dx.doi.org/10.4049/jimmunol.0902761.
48. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25-36. http://dx.doi.org/10.1016/S1074-7613(00)80295-2.
49. Cao T, Meuleman P, Desombere I, Sällberg M, Leroux-Roels G. 2001. In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulinGproduction by HBcAg-specific CD4+ Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model. J Virol 75:11449-11456. http://dx.doi.org/10.1128/JVI.75.23.11449-11456.2001.
50. Cooper A, Tal G, Lider O, Shaul Y. 2005. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol 175:3165-3176. http://dx.doi.org/10.4049/jimmunol.175.5.3165.
51. Tzeng HT, Tsai HF, Chyuan IT, Liao HJ, Chen CJ, Chen PJ, Hsu PN. 2014. Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model. PLoS One 9:e103008. http://dx.doi.org/10.1371/journal.pone.0103008.
52. Kan Q, Li D, Yu Z. 2012. Specific expression of human interferongamma controls hepatitis B virus replication in vitro in secreting hepatitis B surface antigen hepatocytes. J Virol Methods 180:84-90. http://dx.doi.org/10.1016/j.jviromet.2011.12.016.
53. Park SG, Ryu HM, Lim SO, Kim YI, Hwang SB, Jung G. 2005. Interferon---inhibits hepatitis B virus-induced NF-κB activation through nuclear localization of NF-κB-inducing kinase. Gastroenterology 128:2042-2053. http://dx.doi.org/10.1053/j.gastro.2005.03.002.
54. Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV. 2002. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 76:5646-5653. http://dx.doi.org/10.1128/JVI.76.11.5646-5653.2002.
55. Robek MD, Wieland SF, Chisari FV. 2002. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 76:3570-3574. http://dx.doi.org/10.1128/JVI.76.7.3570-3574.2002.
56. Wieland S, Thimme R, Purcell RH, Chisari FV. 2004. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad SciUSA 101:6669-6674. http://dx.doi.org/10.1073/pnas.0401771101.